WO2006134917A1 - 抗体の作製方法 - Google Patents
抗体の作製方法 Download PDFInfo
- Publication number
- WO2006134917A1 WO2006134917A1 PCT/JP2006/311835 JP2006311835W WO2006134917A1 WO 2006134917 A1 WO2006134917 A1 WO 2006134917A1 JP 2006311835 W JP2006311835 W JP 2006311835W WO 2006134917 A1 WO2006134917 A1 WO 2006134917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- vector
- cell
- virus
- minus
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 33
- 239000013598 vector Substances 0.000 claims abstract description 134
- 210000004027 cell Anatomy 0.000 claims abstract description 127
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000013603 viral vector Substances 0.000 claims abstract description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 63
- 239000000427 antigen Substances 0.000 claims abstract description 62
- 102000036639 antigens Human genes 0.000 claims abstract description 62
- 108091007433 antigens Proteins 0.000 claims abstract description 62
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 58
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 58
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 58
- 229920001184 polypeptide Polymers 0.000 claims abstract description 57
- 239000006166 lysate Substances 0.000 claims abstract description 45
- 241001465754 Metazoa Species 0.000 claims abstract description 33
- 210000000628 antibody-producing cell Anatomy 0.000 claims abstract description 17
- 241000282414 Homo sapiens Species 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims description 78
- 241001493065 dsRNA viruses Species 0.000 claims description 67
- 241000711408 Murine respirovirus Species 0.000 claims description 43
- 108010067390 Viral Proteins Proteins 0.000 claims description 26
- 239000013592 cell lysate Substances 0.000 claims description 24
- 238000007912 intraperitoneal administration Methods 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 18
- 210000000952 spleen Anatomy 0.000 claims description 18
- 230000002950 deficient Effects 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 238000011081 inoculation Methods 0.000 claims description 14
- 101150034814 F gene Proteins 0.000 claims description 13
- 238000010255 intramuscular injection Methods 0.000 claims description 12
- 239000007927 intramuscular injection Substances 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 5
- 230000007910 cell fusion Effects 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 238000012827 research and development Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 117
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 75
- 102000004169 proteins and genes Human genes 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 62
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 230000037452 priming Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 27
- 239000006228 supernatant Substances 0.000 description 23
- 238000001262 western blot Methods 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 230000016784 immunoglobulin production Effects 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 210000004408 hybridoma Anatomy 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 18
- 238000010367 cloning Methods 0.000 description 18
- 210000000170 cell membrane Anatomy 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 102000004389 Ribonucleoproteins Human genes 0.000 description 16
- 108010081734 Ribonucleoproteins Proteins 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 14
- 239000012228 culture supernatant Substances 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 101710091045 Envelope protein Proteins 0.000 description 12
- 102000011931 Nucleoproteins Human genes 0.000 description 12
- 108010061100 Nucleoproteins Proteins 0.000 description 12
- 101710188315 Protein X Proteins 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 9
- 102100034349 Integrase Human genes 0.000 description 9
- 108010071390 Serum Albumin Proteins 0.000 description 9
- 102000007562 Serum Albumin Human genes 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 101710181008 P protein Proteins 0.000 description 8
- 101710177166 Phosphoprotein Proteins 0.000 description 8
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000053642 Catalytic RNA Human genes 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 108091092562 ribozyme Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 101150066002 GFP gene Proteins 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- -1 phospho Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000726041 Human respirovirus 1 Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100034574 P protein Human genes 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 241001113283 Respirovirus Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 238000010370 cell cloning Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 208000000655 Distemper Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- ZHNHJYYFCGUZNQ-KBIXCLLPSA-N Glu-Ile-Ser Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O ZHNHJYYFCGUZNQ-KBIXCLLPSA-N 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 2
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 2
- 229960002078 sevoflurane Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IHGSAQHSAGRWNI-UHFFFAOYSA-N 1-(4-bromophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(Br)C=C1 IHGSAQHSAGRWNI-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001455610 Ephemerovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 101150043759 FP gene Proteins 0.000 description 1
- 101150045567 GP16 gene Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150008820 HN gene Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000347881 Kadua laxiflora Species 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 241001182316 Linda Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100340718 Mus musculus Il10 gene Proteins 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940111782 egg extract Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to an antibody and a method for producing an antibody-producing cell.
- antibodies can be used to detect a variety of proteins, including Western blotting, immunohistochemistry, flow cytometry, immunoprecipitation, immunoaffinity column method, and cancer cell missile therapy, vector targeting, It is also widely used in practical applications such as cell function inhibition.
- the present invention provides methods for producing antibodies and antibody-producing cells.
- the present invention also provides a method for producing an antigen composition for producing an antibody.
- a minus-strand RNA virus is a virus having minus-strand RNA in the genome, and when the cell is infected, the genomic RNA is amplified in the cell and the loaded gene is expressed at a high level (Yonemitsu Y. et al., Nat Biotechnol, 2000, 18 (9): 970-3).
- the present inventor considered the use of a minus-strand RNA virus for antibody production taking advantage of this advantage of a minus-strand RNA virus.
- negative-strand RNA viruses have been reported to enhance host immune activity by secreting multiple cytoplasmic ins after infection (Strahle et al. J. Virol. 77 (14): 7903-7913.
- the present inventors produced a recombinant minus-strand RNA virus that expresses a polypeptide desired as an antigen, and immunized the animal to produce an antibody.
- RNA virus or cell lysate (lysate) infected with the virus via multiple routes of administration, including nasal drop, intramuscular injection, direct spleen injection, subcutaneous lumbar region, and footpad injection
- routes of administration including nasal drop, intramuscular injection, direct spleen injection, subcutaneous lumbar region, and footpad injection
- antibodies were detected in blood by any route of administration.
- the increase in antibody titer was particularly noticeable with nasal administration.
- hyperpridoma from immunized mouse spleen cells and successfully produced monoclonal antibodies. It is considered that antibody production was efficiently induced by the immunostimulatory effect of the minus-strand RNA virus vector and high expression of the antigen polypeptide.
- an antibody against the polypeptide can be efficiently produced by inoculating a minus-strand RNA virus vector expressing the antigen polypeptide.
- the place of vector inoculation was not limited, and the boost was effective.
- Immunization can be performed by directly inoculating a negative-strand RNA virus vector, or by using cultured cells infected with the vector, and the prepared cells can be used for immunization in addition to immunization.
- the antibody obtained by the method of the present invention is expected to be applied to a wide range of fields such as detection and separation of biomolecules and antibody therapy.
- the present invention relates to an antibody and a method for producing antibody-producing cells using a minus-strand RNA virus, and more specifically to the invention described in each item of the claims.
- inventions composed of one or more combinations of the inventions recited in the claims that cite the same claim are already intended for the inventions recited in those claims.
- the present invention provides:
- step (b) recovering an antibody or antibody-producing cell from the animal, (2)
- the inoculation in step (a) is performed by an administration route selected from the group consisting of intramuscular injection, subcutaneous administration, nasal administration, palm or footpad administration, spleen administration, and intraperitoneal administration.
- Th2 site force Inca is selected from the group force consisting of SIL_4, IL_10, and IL-13.
- the method of the present invention can efficiently produce an antibody using a minus-strand RNA virus that expresses a desired antigen polypeptide, and it is not essential to purify the antigen peptide.
- Antibodies produced according to the present invention can be used for missile therapy of cancer cells by simply detecting and identifying various proteins such as Western blotting, immunohistochemistry, flow cytometry, immunoprecipitation, and immunoaffinity column method. It can also be used in clinical applications such as vector targeting and cell function inhibition.
- FIG. 1 is a view showing the production of an anti-LacZ antibody by administration of a negative strand RNA virus vector carrying a LacZ gene. Detection was performed with commercially available purified LacZ using mouse plasma 5 weeks after priming by intramuscular injection.
- FIG. 2 is a diagram showing anti-GFP antibody production by administration of a minus-strand RNA virus vector carrying a GFP gene.
- A Primed with nasal injection, intramuscular injection, direct injection of spleen or footpad injection with viral vector, boosted by intraperitoneal administration of the viral vector 2 weeks later, bra Anti-GFP antibody in mouse plasma 4 weeks after imming was detected by Western plot.
- FIG. 3 is a graph showing antibody production by intraperitoneal administration of a minus-strand RNA virus vector-infected cell lysate.
- FIG. 4 is a graph showing the effect of boost by intraperitoneal administration of a minus-strand RNA viral vector on antibody production.
- the boost operation after 2 weeks was performed with DPBS (-).
- FIG. 6 shows the results of Western blot analysis using a hybridoma supernatant (# 6-76) producing an anti-gpl60 monoclonal antibody.
- Hypridoma was produced from the spleen cells of mice inoculated with the minus strand RNA virus vector carrying HIV-1 gpl60 gene, and the hyperidoma producing anti-gpl60 monoclonal antibody was selected. Using this hyperidoma supernatant, the gpl60 protein in the SeV18 + GP160 / AF vector-infected LLC-MK cell lysate
- FIG. 7 shows the determination of subclasses of anti-gpl60 antibodies produced by Hypridoma # 6-76. ⁇ ⁇
- the subclass of anti-gpl60 antibody produced by Hypridoma # 6-76 was determined using the ⁇ zoisotai pink kit (Mouse Immunoglobulin Screemng / Isotyping Kit (Genzyme)).
- the subclass-specific antibody used is shown in the upper part.
- Gl IgG
- G2a IgG
- Ig, ⁇ IgG
- A IgA
- M IgM
- B buffer blank
- N non-immune serum ⁇ negative c
- FIG. 8 is a diagram showing that a hyperidoma producing a monoclonal antibody recognizing HIV-1 gpl60 can be prepared by boosting with a synthetic peptide after priming with a Sendai virus vector.
- the gpl60 protein in the BHK-21 cell membrane fraction infected with SeV18 + GP160 / AF vector was detected by Western plot.
- the membrane fraction was prepared using a commercially available kit (Calb iochem catalog number 539790) according to the instructions.
- the migration positions of gpl60 and gp41 are indicated by arrows on the right side. [Description of each lane] 1. Molecular weight marker 2. Non-infected BHK-21 cell membrane fraction 3. SeV18 + GFP / AF infected BHK-21 cell membrane fraction 4. SeV18 + GP16 0 / ⁇ F infected BHK-21 cell membrane fraction Min
- FIG. 10 Purification by cell cloning of anti-gpl60 antibody-producing hybridoma # 6-76 obtained in Example 6 and anti-gpl60 antibody-producing hybridoma C1-182 obtained by boosting with a synthetic peptide in Example 7
- FIG. 6 is a view showing purification by cell cloning of Hypridoma # 6-76 and the hybridoma C1-182 obtained in Example 7.
- Figure 12 High Pridoma # 6 obtained in Example 6
- IgG H chain and L chain are indicated by arrows on the right side.
- FIG. 13 shows the same Western blot as in Example 7 using the antibody protein purified from the culture supernatant of hybridoma # 6-76-14-29 after cloning twice.
- the purified antibody was compared with the unpurified culture supernatant of # 6-76 and # 6-76-14-29 before cloning. It has been shown that purified antibody recognizes g PL60, gp41 with the same specificity as the previous purification.
- [Description of each lane] 1. Molecular weight marker 2. Non-infected BHK-21 cell membrane fraction 3. SeV18 + GFP / AF infected BHK-21 cell membrane fraction 4. SeV18 + GP160 / ⁇ F infected BHK-21 cell membrane Fraction
- FIG. 14 A diagram showing the results of Western blotting using the culture supernatants of a plurality of anti-gpl60 antibody-producing hyperpridoma obtained in Example 10.
- FIG. c that recognizes the gp41 moiety in gpl60
- the migration positions of gpl60, gpl20, and gp41 are indicated by arrows on the right side.
- [Description of each lane] 1. Molecular weight marker 2. Uninfected BHK-21 cell membrane fraction 3. SeV18 + GFP / AF infected BHK-21 cell membrane fraction 4. SeV18 + GP160 / ⁇ F infected BHK-21 cell membrane fraction.
- FIG. 15 shows that anti-gpl60 antibody is induced in mouse plasma by immunization with Sendai virus vector carrying both mouse IL10 gene and gpl60 gene. Seven mice were used. Blood was collected from the orbit on day 56 after priming. Hypridoma # 6-76 culture supernatant was used as a positive control, and pre-immune mouse plasma (# 1 pre) was used as a negative control. The migration position of gpl60 was indicated by the right arrow and black dots. [Description of each lane] 1. Molecular weight marker 2. Non-infected BHK-21 cell membrane fraction 3. SeV18 + GFP / AF infected BHK-21 cell membrane fraction 4. SeV18 + GP160 / ⁇ F infected BHK-21 cell membrane fraction Min.
- the present invention relates to a method for producing an antibody or antibody-producing cell, which comprises a minus-strand RNA virus vector carrying a nucleic acid encoding a foreign polypeptide to be used as an antigen, a nucleic acid that produces the virus vector, the vector or
- the present invention relates to a method comprising inoculating an animal with a cell into which a nucleic acid for producing the vector has been introduced, or a lysate of the cell, and recovering an antibody or antibody-producing cell from the animal.
- the minus-strand RNA virus is a virus that contains the minus-strand RNA (an antisense strand complementary to the strand that senses the viral protein) as a genome.
- Negative strand RNA viruses are also called negative strand RNA viruses.
- the minus-strand RNA virus used in the present invention is particularly preferably a single-strand minus-strand RNA virus (also referred to as a non-segmented minus-strand RNA virus).
- a “single-stranded negative strand RNA virus” refers to a virus having a single-stranded negative strand [ie, minus strand] RNA in the genome.
- the minus-strand RNA viral vector used in the present invention is a defective vector that does not have the ability to propagate but may or may not have the ability to propagate. May be used.
- “Having a transmission ability” means that when a viral vector infects a host cell, the virus replicates in the cell and infectious virus particles are produced.
- the defective vector include a vector that lacks at least one gene encoding a protein constituting the envelope.
- Specific examples include vectors that lack at least one of the genes that code for envelope-constituting proteins such as F, H, HN, G, M, and Ml, which vary depending on the type of virus (WO00 / 70055). And WO00 / 70070; Li, H.-O. et al., J. Virol. 74 (14) 6564-6569 (2000)).
- minus-strand RNA viruses that are particularly preferably used in the present invention include, for example, Paramyxoviridae virus Sendai virus, Newcastle disease virus, mumps force, Zeunores (mu mps virus) RSasoleus (respiratory syncytial virus) ⁇ bovine plague quinoles (rinde ⁇ est virus), distemper virus (distemper virus), sanorepaline fluenza virus (SV5), human parainfluenza virus Type 1,2,3, Orthomyxoviridae Influenza virus, Rabodoviridae vesicular stomatitis virus, rabies Winores (rab) ies virus) and the like.
- Paramyxoviridae virus Sendai virus Newcastle disease virus
- mumps force Zeunores (mu mps virus)
- RSasoleus respiratory syncytial virus
- bovine plague quinoles rinde ⁇ est virus
- distemper virus distemper virus
- the paramyxovirus is preferably a virus belonging to the Paramyxovirinae family (including the genera Respirovirus, Rubravirus, and Mobile virus), more preferably the Respirovirus genera.
- Derivatives include viruses in which the viral gene is altered and chemically modified viruses so as not to impair the ability of the gene to be introduced by the virus.
- respirovirus viruses to which the present invention can be applied include human parainfluenza virus type 1 (HPIV-1), human parainfluenza virus type 3 (HPIV-3), and ushipaline fluenza virus type 3 (BPIV).
- the paramyxovirus is most preferably Sendai virus.
- Sendai virus also called mouse parainfluenza virus type 1
- monkey parainfluenza virus type 10 SPIV-10
- the paramyxovirus is most preferably Sendai virus.
- These viruses may be derived from natural strains, wild strains, mutant strains, laboratory passage strains, and artificially constructed strains.
- each gene in each virus belonging to the Paramyxovirus subfamily is generally expressed as follows.
- the NP gene is also denoted as “N”.
- HN is expressed as H (hemagglutinin) when it does not have neuraminidase activity.
- the minus-strand RNA viral vector can encode a desired foreign polypeptide to be used as an antigen in genomic RNA.
- the foreign polypeptide is not limited as long as it is a polypeptide that does not have a natural negative-strand RNA virus, and is a full-length natural protein or a partial fragment thereof (7 amino acids or more, preferably 8, 10 or 15 amino acids or more). Or a fusion polypeptide of these and other polypeptides.
- a recombinant viral vector encoding a foreign polypeptide can be obtained by inserting a gene encoding the polypeptide antisense into the genome of a minus-strand RNA viral vector.
- a desired site in the protein non-coding region of the viral genome can be selected as the gene insertion position.
- each viral protein is located between the 3 ′ leader region of genomic RNA and the viral protein ORF closest to the 3 ′ end. It can be inserted between the ORF and / or between the viral protein ORF closest to the 5 'end and the 5' trailer region.
- an envelope protein gene such as the M, F, or HN gene, it may be inserted into the deleted region.
- E-I-S sequence should be constructed between the inserted foreign gene and the viral ORF. Two or more foreign genes can be inserted in tandem via the E-I-S sequence.
- the expression level of a foreign gene can be regulated by the type of transcription initiation sequence added upstream of the gene (3 ′ side of the negative strand (negative strand)) (WO01 / 18223). It can also be controlled by the position of the foreign gene inserted on the genome, and the higher the expression level is, the lower the expression level is. Become.
- a gene encoding a foreign polypeptide can be linked to a highly efficient transcription initiation sequence and inserted near the 3 ′ end of the minus-strand genome. preferable. Specifically, it is inserted between the 3 'leader region and 3' and the viral protein ORF.
- the viral protein gene closest to 3 ′ and the ORF of the second viral protein gene may be inserted between the viral protein gene closest to 3 ′ and the ORF of the second viral protein gene, or between the second and third viral protein genes from 3 ′.
- the closest to the 3 'genome the viral protein gene is the N gene
- the second gene is the P gene
- the third gene is the M gene.
- the insertion position of the foreign gene should be set as 5 'as possible in the minus-strand genome, or the transcription initiation sequence should be made less efficient. Thus, it is possible to obtain an appropriate effect by keeping the expression level from the virus vector low.
- Particularly preferred are 3'-UCCCAGUUUC-5 '(SEQ ID NO: 2), 3'-UCCCACUUAC-5, (SEQ ID NO: 3), and 3'-UCCCACUUUC_5' (SEQ ID NO: 4).
- the E sequence of Sendai virus vector is preferably, for example, 3′-AUUCUUUU-5 ′ (SEQ ID NO: 8) (5′-TAAGAAAAA-3 ′ (SEQ ID NO: 9) for DNA encoding a plus strand).
- 3′-GAA-5 (specifically, 5 and CTT-3 ′ for plus-strand DNA) may be used as the I sequence.
- Recombination of the recombinant RNA virus vector may be performed using a known method. Specifically, (a) minus-strand RNA virus genome that expresses a desired foreign antigen polypeptide in the presence of a viral protein that constitutes an RNP containing the minus-strand RNA virus genome RNA in mammalian cells. A step of transcribing DNA encoding RNA or its complementary strand (antigenomic RNA, plus strand), (b) produced minus strand RNA virus or The ability to produce RNP containing the genomic RNA can be achieved.
- the above-mentioned viral proteins constituting RNP are proteins that form RNP together with viral genomic RNA and constitute a nucleoside psid.
- N nucleocapsid (or nucleoprotein (NP))
- P phospho
- L large proteins.
- N nucleocapsid
- P phospho
- L large proteins.
- N nucleocapsid
- P phospho
- L large proteins.
- Corresponding proteins are known to those skilled in the art (Anjeanette Robert et al., Virology 247: 1-6 (1998)).
- N may be written as NP
- RNA genome that is, the same antisense strand as the virus genome
- a plus-strand RNA antigenome; complementary strand of genomic RNA
- a positive strand is preferably generated.
- the viral genomic RNA encodes a viral protein necessary for reconstitution of RNP
- the gene encoding the envelope protein may be deleted. Specifically, for example, if N, P, and L proteins are encoded, viral proteins such as F, H N, and M may not be encoded.
- Such defective viruses are useful as highly safe gene transfer vectors because they do not release infectious virus particles capable of amplifying genomic RNA in cells (WO00 / 70055, WO00 / 70070, and WO03 / 025570). Li, H.—O. et al., J. Virol. 74 (14) 6564-6569 (2000)).
- these envelope-constituting proteins are separately expressed in virus-producing cells to complement particle formation.
- a vector in which DNA encoding the protein or genome is linked downstream of an appropriate promoter is introduced into a host cell.
- the promoter for example, CM V promoter, CAG promoter and the like are used (Niwa, H. et al. (1991) Gene. 108: 193-199, Japanese Patent Laid-Open No. 3-168087).
- the RNA ends accurately reflect the ends of the 3 'leader sequence and the 5' trailer sequence as in the case of the natural viral genome.
- a self-cleaving ribozyme is added to the 5 ′ end of the transcript, and the end of the minus-strand RNA winores genome is accurately excised by the ribozyme (Inoue, K. et al. J. Virol. Methods 107, 2003, 229-236).
- a RNA polymerase recognition sequence of bacteriophage is used at the transcription start site, and the RNA polymerase is expressed in the cell to induce transcription.
- Escherichia coli T3 and T7 phages and Salmonella SP6 phages are used as RNA polymerases for butteriophage (Krieg, PA and Melton, DA 1987, Methods Enzymol. 155: 397—15; Milligan, JF et al. al, 1987, Nucleic Acids Res. 15: 8783-798; Pokrovskaya, ID and Gurevich, VV, 1994, Anal. Biochem. 220: 420-23).
- Batteriophage RNA polymerase can be supplied using, for example, vaccinia virus expressing it (Fuerst, TR et al., Pro Natl. Acad. Sci.
- the 3' end of the transcript is encoded with a self-cleaving ribozyme and this ribozyme is used to accurately 3 ' The edges are cut out (Hasan, ⁇ ⁇ ⁇ ⁇ et al "J. Gen. Virol. 1997: 78; 2 813-2820, Kato, A. et al., EMBO J. 1997,: 16; 578- 587 and Yu, D. et al "Genes Cells. 1997: 2; 457-466).
- a ribozyme a self-cleaving ribozyme derived from the antigenomic strand of hepatitis delta virus can be used.
- the infectivity of the virus may be complemented with the missing envelope constituent protein.
- an envelope protein different from the deleted protein may be used. You can also make it a pseudo type.
- V protein (VSV-G) of Vesicular stomatitis virus (VSV) (J. Virology 39: 519-528 (1981)) can be used (Hirata , T. et al., 2002, J. Virol. Methods, 104: 125-133; Inoue, M. et al., 2003, J. Virol. 77: 6419-6429; Inoue M. et al., J Gene Med.
- genes to be deleted from the genome include spike protein genes such as F, HN, H, and G, envelope lining protein genes such as M, and any combination thereof. Deletion of spike protein gene is effective to make negative-strand RNA virus vector non-transmissible, and deletion of protein gene behind envelope such as M protein makes particle formation from infected cells impossible. It is effective to For example, F gene-deleted negative-strand RNA virus vectors (Li, H.-O. et al., J. Virol. 74, 6 564-6569 (2000)), M gene-deleted negative-strand RNA viral vector (Inoue, M. et al., J. Virol.
- 77, 6419-6429 (2003)) and the like are preferably used.
- a vector lacking the F gene pathogenicity in the host mouse was suppressed, and it was possible to realize good antibody production (see Examples).
- Vectors lacking any combination of at least two genes of F, HN, and H) and M are more secure.
- both M and F gene deletion-type vectors are non-transmissible and lack particle formation while maintaining a high level of infectivity and gene expression ability.
- F gene-deficient recombinant virus examples include, for example, a minus-strand RNA virus genome deficient in the F gene or a plasmid expressing its complementary strand, and an expression vector that expresses the F protein.
- an expression vector that expresses the F protein As well as N, P, and L protein expression vectors.
- viruses can be produced more efficiently by using host cells in which the F gene is integrated into the chromosome (WO00 / 70070).
- an envelope protein gene is included in a vector having a recombinant enzyme target sequence such as Cre / loxP-inducible expression plasmid pCALNdlw (Arai, T. et al., J. Virology 72, 1998, pi 115-1121).
- the minus-strand RNA virus used in the present invention may have an accessory gene deficient.
- knocking out the V gene which is one of the accessory genes of Sendai virus (SeV) significantly reduces the pathogenicity of SeV against hosts such as mice that do not impair gene expression and replication in cultured cells ( Kato, A. et al., 1997, J. Virol. 71: 7266-7272; Kato, A. et al., 1997, EMBO J. 16: 578-587; Curran, J. et al., WO01 / 04272 , EP1067179).
- a minus-strand RNA virus having a mutation in the P gene or L gene may be used in order to increase the persistence of infection.
- mutations include Se Examples include mutation of the 86th Glu (E86) of the VP protein, substitution of the SeV P protein with the other amino acid of the 511st Leu (L511), or substitution of homologous sites of other minus-strand RNA virus P proteins. Specific examples include substitution of the 86th amino acid with Lys and substitution of the 511st amino acid with Phe.
- Specific examples include substitution of the 1197th amino acid with Ser, and the substitution of the 1795th amino acid with Glu. Mutations in the P and L genes can significantly enhance the effects of persistent infectivity, suppression of secondary particle release, or suppression of cytotoxicity.
- Th2 site force-in refers to a site force-in produced predominantly in type 2 helper T cells (Th2 cells) over type 1 helper T cells (Thl cells).
- Th2 cells type 2 helper T cells
- Thl cells type 1 helper T cells
- Anti-inflammatory site force-in is a generic term for polypeptides that act in the direction of suppressing inflammation, and is a signaling molecule that promotes signal transduction that suppresses inflammation and / or Signaling molecules that inhibit signal transduction that promote inflammation (eg, inflammatory site force in inhibitors) are included.
- the anti-inflammatory site force-in specifically includes interleukin (IL) _4, IL-10, IL_11, IL_13, TGF- ⁇ , soluble TNF-receptor, and IL-l receptor antagoni st (IL- lra).
- the vector-encoded Th2 site force-in and / or anti-inflammatory site force-in may be a partial peptide (such as an active fragment) as long as the activity of the natural polypeptide is maintained. For example, deletion of N-terminal and / or C-terminal amino acid residues (eg 1-30 amino acids, more particularly 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids) There is a high possibility that it will not affect the activity of Site Force Inn.
- soluble fragments of inflammatory site force-in receptor including ligand binding domain
- antibodies or antibody fragments that bind to the ligand binding domain of inflammatory site force-in receptor including inflammatory site force Polypeptides that inhibit in signal transduction may be used.
- Th2 site force-in and / or anti-inflammatory site force-in also includes mature polypeptides with the signal sequence removed.
- the desired fragment can be used, and the signal sequence of the desired protein can be appropriately used as the N-terminal signal sequence for secretion outside the cell.
- a signal sequence of a desired secretory protein such as interleukin (IL) _2 or tissue plasminogen activator (tPA) can be used, but it is not limited thereto. Alternatively, it may be expressed as a fusion protein with another peptide.
- the Th2 site force-in is more preferably a site force in selected from the group consisting of IL_4, IL_10, IL_13, and TGF-beta force, and most preferably IL-10.
- the nucleotide sequence and amino acid sequence of each site force in gene are known (IL_4: NM_000589, NP_000580, AAH66277, AAH67515, NP_758858, NP.067258, NP.958427; IL-10: NM_000572, NP_000563, CAG46825, NP .034678, NP.036986; IL-13: NM_002188, NP .002179, AAB01681, NP_032381, NP.446280; TGF-beta (transforming growth factor -beta): M_60316) o
- each Th2 site force-in or anti-inflammatory site force-in can be detected by a known method.
- a method for detecting activity by proliferation assay using mouse mast cell MC / 9 (ATCC CRL-8306), human erythroleukemia cell line TF-1 (ATCC CRL-2003), etc. is known.
- Thompson-Snipes Shi et al., 1991, J. Exp. Med. 17 3: 507—510; Kruse N et al., EMBO J.
- Th2 site-in or anti-inflammatory site-in deletion mutants prepared using genetic recombination techniques can be assembled by this method to identify active fragments.
- ED effective dose
- activity for example, the reciprocal of ED
- the activity is 50% or more, preferably 60% or more, 70% or more, 80% or more, 90% or more Or a partial peptide of 95% or more is recommended.
- mice which are not particularly limited by the origin of vector-encoded Th2 site-in and / or anti-inflammatory site-in It is appropriate to use those derived from the same species as the force administration target that can use any of mammals such as nu, chimpanzee, monkey, and human.
- the nucleotide sequence can be obtained from the database as described above. For example, in the case of mouse IL-10, Genbank Accession No. AY410237, NM_010548, hi HL-10, Genbank Accession No. AY029171 NM.000572.
- the minus-strand RNA virus of the present invention does not encode a polypeptide containing a protein involved in a desired disease or a partial peptide thereof (for example, a partial peptide of 9, 8, 7, 6, or 5 amino acids or more). be able to.
- diseases include neurodegenerative diseases, and examples of proteins involved in neurodegenerative diseases include amyloid ⁇ .
- mammalian cells can be used for virus production, specifically, for example, LLC-MK cells derived from monkey kidney (ATCC CCL-7) and CV-1 cells (such as ATCC CCL-7) and CV-1 cells (such as ATCC CCL-7) and ATCC CCL-7) and ATCC CCL-7) and ATCC CCL-7) and CV-1 cells (such as ATCC CCL-7) and ATCC CCL-7) and ATCC CCL-7) and ATCC CCL-7 cells (ATCC CCL-7) and CV-1 cells (such as ATCC CCL-7).
- ATCC CCL-7 monkey kidney
- CV-1 cells such as ATCC CCL-7
- CC CCL-70 BHK cells derived from hamster kidney (eg, ATCC CCL-10), human-derived cells, and the like.
- a viral vector production method using chicken eggs has already been developed (Nakanishi et al. (1993), “Advanced Protocols for Neuroscience Research, Molecular Neuronal Physiology”, Koseisha, Osaka, pp.153-172). Specifically, for example, fertilized eggs are placed in an incubator and cultured at 37-38 ° C for 9-12 days to grow embryos.
- Viral vector is inoculated into the allantoic cavity and eggs are cultured for several days (eg 3 days) to propagate the viral vector. Conditions such as the culture period may vary depending on the recombinant Sendai virus used. Then collect the urine containing the virus. Separation and purification of Sendai virus vector from urine can be carried out according to conventional methods (Yasuto Tashiro, “Virus Experiment Protocol”, supervised by Nagai and Ishihama, Medical View, pp.68-73, (1995))
- the recovered viral vector can be purified to be substantially pure.
- the purification method can be performed by a known purification / separation method including filtration (filtration), centrifugation, adsorption, column purification, or any combination thereof.
- “Substantially pure” means that the virus component occupies a major proportion in the solution containing the virus vector.
- a substantially pure viral vector composition has 10% of the total protein contained in the solution (excluding proteins prepared as carriers and stabilizers) as a component of the viral vector ( Weight / weight) or more, preferably 20% or more, more preferably 50% or more, preferably 70% or more, more preferably 80% or more, and further preferably 90% or more.
- a paramyxovirus vector as a specific purification method, a method using a cellulose sulfate ester or a crosslinked polysaccharide sulfate ester (Japanese Examined Patent Publication No. 62-30752, Japanese Examined Patent Publication No. 62-33879, and Japanese Examined Publications). No. 62-30753), and a method of adsorbing to a sulfated-fucose-containing polysaccharide and / or a degradation product thereof (WO97 / 32010) and the like.
- a minus-strand RNA viral vector, a nucleic acid that produces the viral vector, the vector or a cell into which the nucleic acid that produces the vector has been introduced, or a lysate thereof, and a desired pharmacologically acceptable carrier or medium A composition for antibody production is combined.
- the composition for producing an antibody is a composition used exclusively for the purpose of producing an antibody.
- “Pharmaceutically acceptable carrier or vehicle” includes any desired solution capable of suspending viral vectors or cells, such as phosphate buffered saline (PBS), sodium chloride solution. , Ringer's solution, culture solution, and the like.
- the present invention includes a minus-strand RNA viral vector carrying a nucleic acid encoding a foreign polypeptide to be used as an antigen, a nucleic acid that generates the viral vector, a cell into which the vector or a nucleic acid that generates the vector has been introduced, or the cell
- the present invention relates to a method for producing an antigen vector composition for producing an antibody, comprising a step of producing a composition comprising a lysate of the above and a pharmaceutically acceptable carrier or medium.
- the present invention also relates to the use of a minus-strand RNA virus vector, a nucleic acid that produces the virus vector, a cell into which the vector or a nucleic acid that produces the vector has been introduced, or a lysate thereof in the production of a composition for producing an antibody. Also related.
- a recombinant minus-strand RNA viral vector carrying a nucleic acid that encodes a foreign polypeptide desired to be used as an antigen the above description of the present specification may be referred to.
- the composition for producing an antibody can be supplemented with an immunoactivator such as cytokinin, cholera toxin, and salmonella toxin.
- Miyuban complete Freund's adjuvant, incomplete Freund's adjuvant, MF59 (oil emulsion), MTP-PE (mura myl tripeptide derived from mycobacterial cell wall) ⁇ or QS—21 soapbark tree Quilaia saponana), Alum (hydroxylic acid)
- Adjuvants such as aluminum compound particles such as aluminum phosphide, aluminum sulfate, and aluminum phosphate can also be combined.
- the composition preferably further contains Th2 site force-in or a nucleic acid encoding Th2 site force-in.
- Th2 site force-in a nucleic acid encoding other anti-inflammatory site force-in or anti-inflammatory site force-in alone or in combination with a nucleic acid encoding Th2 site force-in or Th2 site force-in described above may be included.
- the Th2 cytokine or anti-inflammatory cytokine those described in the present specification and combinations thereof can be used.
- the Th2 site force-in is also selected as a group force that also includes IL-4, IL-10, and IL-13 forces.
- the composition can also include a Th2 adjuvant.
- Th2 adjuvant is an adjuvant that activates type 2 helper T cells (Th2 cells) over type 1 helper T cells (Thl cells), specifically alum mum hydroxide alum), cholera toxin (B sub image t), Schistosoma mansom egg extract protein (eg Lacto-N-fticopentaose ⁇ ), etc. can be used (Grun, J. and P H.
- an organic substance such as a biopolymer, an inorganic substance such as hydroxyapatite, specifically a collagen matrix, a polylactic acid polymer or copolymer, a polyethylene glycol polymer or copolymer, and a chemical derivative thereof can be combined as a carrier.
- the antigen polypeptide is expressed and antibody production is induced.
- the vector can be administered in vivo or ex vivo via cells.
- the minus-strand RNA Winoresector that is inoculated has the ability to express the antigenic polypeptide gene on its genome, it can be a non-infectious virus particle or virus core ( RNP complex including genome and genome-binding virus protein).
- the minus-strand RNA viral vector includes an infected cell containing a ribonucleoprotein (RNP) complex having genomic RNA derived from a minus-strand RNA virus and a viral protein necessary for the replication of the RNA and the expression of the loaded gene.
- RNP ribonucleoprotein
- the RNP is a complex containing, for example, genomic RNA of a negative strand RNA virus or a complementary strand thereof (antigenomic RNA) and N, L, and P proteins.
- the minus-strand RNA viral vector includes genomic RNA and genomic RNA, such as viral infectious particles, non-infectious particles (also called virus-like particles; also referred to as VLPs), and minus-strand RNA viral nucleosides.
- genomic RNA such as viral infectious particles, non-infectious particles (also called virus-like particles; also referred to as VLPs), and minus-strand RNA viral nucleosides.
- RNPs that contain viral proteins that bind. Even if it is RNP (virus core) from which the envelope has been removed from the virus particle, it can replicate the viral genomic RNA in the cell if it is introduced into the cell (W097 / 16538; W00 / 70055).
- RNP or VLP can be inoculated into animals together with, for example, a transfection reagent (WO00 / 70055; WO00 / 70070).
- RNA viral vector When inoculated via cells, collected from appropriate cultured cells or inoculated animals Introduce minus-strand RNA viral vector into cells. When infecting cells with a minus-strand RNA virus outside the body (for example, in a test tube or petri dish), it is performed in vitro (or ex vivo) in a desired physiological aqueous solution such as a culture solution or physiological saline. At this time, M0I (multiplicity of infection; number of infectious viruses per cell) is preferably between 1 and 1000, more preferably 2 to 500, more preferably 3 to 300, and even more preferably. 5 to 100.
- the contact between the minus-strand RNA virus and the cells is sufficient even for a short time, for example, 1 minute or more, preferably 3 minutes or more, 5 minutes or more, 10 minutes or more, or 20 minutes or more. It may be about 5 minutes to 30 minutes. Of course, it may be contacted for a longer time, for example, for several days or longer.
- RNP containing virus genomic RNA or non-infectious virus particles virus-like particles (VLP)
- VLP virus-like particles
- a known transfection method can be used. Specifically, calcium phosphate (Chen, C. & Okayama, H. (1988) BioTechniques 6: 632-63 8; Chen, C. and Okayama, ⁇ , 1987, Mol. Cell. Biol. 7: 2745), DEAE-dextran (Rosenthal, N. (1987) Methods Enzymol. 152: 704-709), various ribosome-based transcription reagents (Sambrook, J. et al.
- transfection reagents include DO TMA. (Roche), Superfect Transfection Ragent (QIAGEN, Cat No.
- Envelope viruses are known to take up host cell proteins during virus particle formation, and these proteins are antigens when introduced into cells. (J. Biol. Chem. (1997) 272, 16578-16584). Therefore, it is beneficial to use RNP with the envelope removed.
- an expression vector that expresses viral genomic RNA and an expression vector that encodes viral proteins (N, P, and L proteins) necessary for replication of the genomic RNA are introduced into the cell, and the virus is introduced into the cell.
- RNPs can also be formed directly. Cells into which a viral vector has been introduced may be produced in this way.
- the obtained cells are inoculated to the animals as lysates (lysates) as they are or after lysis.
- the lysate of vector-infected cells can be prepared by lysing cell membranes with detergents or by repeatedly freezing and thawing.
- the surfactant nonionic Triton X-100, Nonidet P-40 or the like is used at a concentration of 0.1 to 1%.
- the cell mass recovered by centrifugation after washing with PBS is resuspended in TNE buffer [25 mM Tris-HCl (pH 7.5), 150 mM NaCl, ImM EDTA, 1% Nonidet P_40] and left on ice for 10 to 30 minutes. Obtained at. If the protein used as an antigen is soluble in the cytoplasm, the resulting lysate should be centrifuged (10,000 X g, 10 min) to remove unnecessary insoluble fraction as a precipitate, and the supernatant should be used for immunization. it can.
- Lysates used at the site of administration where it is not desirable to use a detergent can be obtained by repeatedly freezing and thawing the cells re-suspended in PBS 5-6 times after washing.
- the method for producing an antibody or antibody-producing cell of the present invention comprises a negative-strand RNA virus vector carrying a nucleic acid encoding a foreign polypeptide as an antigen before inoculation to an animal, and a nucleic acid for producing the viral vector.
- the method may further comprise the step of preparing a cell into which the vector or the nucleic acid that generates the vector has been introduced, or preparing a lysate of the cell, and any combination thereof.
- a minus strand that expresses a target antigen polypeptide in an animal by administering to the animal a nucleic acid that generates a minus-strand RNA viral vector carrying a nucleic acid encoding a foreign polypeptide that is to be used as an antigen.
- the nucleic acid that produces the minus-strand RNA viral vector is a set of nucleic acids that express the RNA and protein groups necessary for the production of a recombinant of the minus-strand RNA viral vector.
- the negative strand R encoding the desired foreign polypeptide A set of nucleic acids containing nucleic acids encoding NA virus genomic RNA or its complementary strand (antigenomic RNA, plus strand), and the viral proteins that comprise the RNP containing genomic RNA of minus strand RNA viruses.
- These nucleic acids contain an appropriate promoter so that the encoded RNA and protein can be expressed.
- CMV promoter Ferturing, MK, and Hofstetter H. Gene 1986; 45: 101-10 5
- retrovirus LTR Shinnik, TM, Lerner, RA & Sutcliffe (1981) Nature, 293 , 543-548
- EF1 promoter CAG promoter (Niwa, H.
- a plasmid vector can be suitably used as the nucleic acid.
- the genome of the minus-strand RNA virus contains genes encoding viral proteins (typically N, L, and P) that constitute the RNA containing genomic RNA, and is possessed by the parental wild-type virus. Those with all envelope protein genes are preferred.
- an envelope protein that complements the formation of infectious virus particles for example, an envelope protein or VSV-G that is deleted in the genome).
- Nucleic acids encoding other envelope proteins may be included in the above set of nucleic acids. By administering these nucleic acids to animals, recombinant minus-strand RNA viruses are generated in the animals.
- the virus protein group that constitutes the RNP containing the genomic RNA of the minus-strand RNA virus is a protein that forms an RNP with the viral genomic RNA and constitutes the nucleoside psid. These are a group of proteins required for genome replication and gene expression, typically N, P, and L proteins.
- the present invention comprises (a) (i) a nucleic acid encoding a minus-strand RNA viral genomic RNA encoding a foreign polypeptide or a complementary strand thereof, and (ii) a nucleic acid encoding N, P, and L protein, respectively. And (b) recovering an antibody or antibody-producing cell from the animal.
- inoculated norate there is no particular limitation on the inoculated norate, but for example, intramuscular injection (for example, gastrocnemius), subcutaneous administration, nasal administration, intrapalpal or footpad administration, spleen direct administration, intraperitoneal administration and the like are suitable.
- Nasal administration includes the case where the infection site stays in the nasal cavity (intranasal administration) to the respiratory tract to the lungs (intranasal lung administration).
- transanal (rectal) administration may be used, and target organs include the oral cavity, intestinal tract, urogenital or upper respiratory tract mucosa, and the like.
- target organs include the oral cavity, intestinal tract, urogenital or upper respiratory tract mucosa, and the like.
- oral administration in order to maintain transportability even when exposed to gastric juice with strong acidity, it is possible to infect target organs by processing into sustained release microcapsule vectors.
- the inoculation site may be one site or a plurality of sites (for example, 2 to 15 sites).
- the inoculation amount may be appropriately adjusted according to the inoculated animal, the inoculation site, the number of inoculations, and the like.
- the inoculation amount per site is 1 ⁇ 10 4 CIU to 5 ⁇ 10 11 CIU (cell infectious unit), preferably 1 ⁇ 10 6 CIU to 1 ⁇ 10 1 in terms of virus titer. Let's say CIU.
- the same type of cultured cell line for example, sarcoma cell line
- a minus-strand RNA virus vector for example, 10 4 to 10 9 cells, preferably 10 5 ⁇ 10 8 cells, or lysates thereof, can be inoculated into animals.
- a significant antibody titer can be induced by the first immunization alone, but boosting by more than one inoculation will increase the antibody titer. Can be raised.
- RNA viral vector encoding the antigen those further encoding Th2 site force-in and / or anti-inflammatory site force-in can be preferably used.
- Th2 site force-in and / or anti-inflammatory site force-in may be administered.
- the administration site is not particularly limited, but it is administered at the same location as or around the minus-strand RNA virus vector encoding the antigen (1 mm force, within 3 cm, preferably 3 mm force, within 10 mm). Good.
- nucleic acid encoding the minus-strand RNA viral genomic RNA encoding the foreign polypeptide or its complementary strand, and N, P, and L The nucleic acid encoding the protein may be administered to the animal at a weight ratio of 5: 0.5: 0.5: 2, respectively, but the amount ratio of each nucleic acid may be appropriately adjusted.
- an expression plasmid 5 ⁇ g to 1000 ⁇ g of a plasmid encoding viral genomic RNA (plus or minus strand), N, P, and L expression plasmids of 0.5 ⁇ ig / ig 200 ig, 0.5 ⁇ ⁇ 200 / 1 ⁇ , 2/1 ⁇ ⁇ 500 ⁇ when administered Yo Le.
- the nucleic acid is administered by, for example, naked DNA injection or mixing with a transfection reagent.
- transfection reagent examples include ribofactamine or polycationic ribosome.
- Specific examples include DOTMA (Roche), Superfect (QIAGEN # 3 01305), DOTAP, DOPE, DOSPER (Roche # 1811169), TransIT—LTl (Minis, Product No. MIR 2300) can be used.
- Boost is inoculated in the same manner as described above 1 to several weeks after the first immunization (eg:! To 3 weeks, more specifically about 2 weeks later).
- intraperitoneal administration and / or boosting by intradermal injection to the back, toes, etc. are suitable. If you want to increase the antibody titer, repeat the boost.
- the animal is inoculated with an antigen purified from the cell lysate or an antigen purified from the cell lysate.
- Cell lysates for boost immunization can be prepared as described above.
- the degree of purification of the purified antigen is not particularly limited, and it may be purified to various degrees.
- an antigen purified from a lysate by centrifugation, filtration, dialysis, various types of chromatography, or the like can be used. It is also suitable to inoculate a foreign polypeptide or a partial peptide that is to be used as an antigen.
- a partial peptide can be synthesized and immunized with a carrier protein such as KLH (keyhole limpet hemocyanin), ushi serum albumin (BSA), thyroglobulin (THY), or ovoalbumin (OVA) as appropriate.
- KLH keyhole limpet hemocyanin
- BSA ushi serum albumin
- THY thyroglobulin
- OVA ovoalbumin
- the length of the partial peptide should be, for example, 8 to 25 residues (9-20, 10-18, or 12-16 residues).
- the antibody is collected by blood collection (in the case of a polyclonal antibody).
- blood collection in the case of a polyclonal antibody.
- cells are collected from the spleen or lymph node of the immunized animal, immortalized by operations such as cell fusion with myeloma to produce a hyperidoma, and then the desired antibody is produced.
- animals to be inoculated include fish, amphibians, reptiles, birds, mammals and other desired non-human vertebrates having antibodies, but preferred and non-human mammals, more preferably non-human mammals. Is an animal. Specific examples include rodents such as chickens, rabbits, goats, sheep, pigs, rabbits, mice and rats, non-human primates such as monkeys, and other mammals.
- the antibody titer is determined by ELISA (Enzyme-linked immunosorbent assay) or Octaroni method ( ⁇ uc hterlony method).
- ELISA Enzyme-linked immunosorbent assay
- Octaroni method ⁇ uc hterlony method
- the ELISA method for example, after the antigen is adsorbed to the microplate, the prepared antiserum is diluted 1000-fold to 2-fold and added to the plate to cause the antigen-antibody reaction. Further, as a secondary antibody, a peroxidase enzyme-labeled heterologous animal antibody against the antibody of the immunized animal is reacted and then developed.
- the antibody titer can be calculated by using the dilution ratio at which the color developing absorbance is 1 ⁇ 2 of the maximum color developing absorbance as the antibody titer of the antibody.
- the Octaloni method Ouchteriony method
- the antigen and antibody diffuse in the agar gel, resulting in an immunoprecipit
- the antibody may be prepared in the form of serum or a diluted solution thereof, or may be purified.
- a desired class such as IgG or IgM antibody can be purified.
- a column or bead in which Protein A or Protein G is immobilized on a carrier can be used.
- An IgM antibody can be purified by a column using 2-mercaptopyridine as a ligand. The 2-mercaptopyridine column is also used for purification of IgY (chicken egg yolk antibody) (HiTrap Ig Y Purification HP, Amersham Biosciences ⁇ ⁇ ⁇ .).
- the antibody can be purified by DEAE anion exchange chromatography. For example, when purifying a large amount from goats, hidges, etc., first salt out with sulfate to obtain a crude IgG fraction, and then pass through a DEAE-cellulose column. Collected in minutes.
- an affinity purification method can be used as a method for specifically purifying an antibody from antiserum. The ability to specifically recover antibodies that bind to antigens by immobilizing the antigen on a carrier gel, preparing an affinity gel, passing antiserum through this gel, and recovering the IgG bound to the antigen S it can.
- the collected antibody can be analyzed for purity by HPLC (for example, Tosoh TSK G3000 SWXL column) (Howard, CC and Bathell, DR eds., Basic Methods in Antibody Production and Characterization, 2001, CRC Press BocaRaton, London, New Yorkj 0
- an antibody that does not bind to the target antigen polypeptide can be removed by negative selection.
- minus-strand RNA virus Antibodies that bind to the viral proteins of can be removed. This can be accomplished, for example, by encoding the antigenic polypeptide of interest, a minus-strand RNA viral vector, a cell into which the viral vector has been introduced, a lysate of the cell, or one or more of the viruses.
- a viral protein may be prepared and the antibody binding thereto may be removed.
- a solution containing an antibody is added to the minus-strand RNA vinores betater that does not encode the target antigen polypeptide, a cell into which the viral vector has been introduced, a lysate of the cell, or a viral protein of the virus.
- a solution containing an antibody is added to the minus-strand RNA vinores betater that does not encode the target antigen polypeptide, a cell into which the viral vector has been introduced, a lysate of the cell, or a viral protein of the virus.
- the immobilized carrier gel to remove the antibody binding to them.
- a solution containing an antibody produced by a hyperidoma is mixed with a protein that does not encode the antigen polypeptide of interest, a minus-strand RNA virus vector, a cell into which the virus vector is introduced, a lysate of the cell, or the virus It is mixed with the virus protein and the binding is detected.
- hybridomas that produce antibodies that do not bind to these it is possible to exclude hybridomas that produce antibodies that bind to the viral vector itself.
- the obtained antibody can be stored in the form of a solution or a lyophilized product.
- sodium azide may be added as a preservative. It may also contain ushi serum albumin (BSA) as a stabilizer.
- BSA ushi serum albumin
- the antibody can be diluted in phosphate buffered saline containing 2 mg / mL ushi serum albumin and 0.1% sodium azide.
- Applications of antibodies include, for example, analysis of surface antigens by flow cytometry, analysis of intracellular antigens by flow cytometry, immunohistochemical staining, immunoblotting (u stampblot), immunoprecipitation, ELISA, ELISP T, in vivo, bioaccess, blocking, neutralization, antibody therapy, etc.
- Bioassays For in vivo applications, antibodies that do not contain preservatives such as sodium azide are preferred. When used for protein detection, the antibody can be labeled appropriately.
- various labeling methods such as enzyme labeling, fluorescent labeling, radioactive labeling, piotin labeling, and gold colloid labeling are known (P. Cuatrecasas, et al, Biochemistry). , 11, 2291 (1972); S. Yoshitake, et al., Eur. J. Biochem., 101, 395 (1979); MJ O'S ullivan, et al., Anal. Biochem., 100, 100 (1979); S. Yoshitake, et al "Anal.
- the photochromic dyes are: FITC, PE, ECD (PE-TxRED), PC5 (PE_Cy5), PC 5.5 (PE-Cy5.5), PC7 (PE-Cy7) APC, APC5.5 (APC_Cy5.5), APC7 (APC_Cy7), Cy5, Alexa Fluor TM, etc. are used.
- the antibody is fragmented and F (ab '), Fab', Fab, F
- Antibody fragments can be obtained by degrading antibodies using peptidases such as papain or pepsin.
- a 6-week-old male BALB A mouse LacZ-expressing F gene-deficient Sendai virus vector SeV18 + LacZ / AF (W ⁇ 00 /) was prepared in 6 gastrocnemius muscles with saline to 2xl0 8 CIU / ml. 70070) was administered. 100 ⁇ was inoculated at two sites on one side by intramuscular injection. Five weeks after vector inoculation, blood was collected from the orbital venous plexus and plasma was separated.
- SDS electrophoresis was performed using a commercially available Escherichia coli-derived j3 galactosidase (Sigma G5635) to 4 ⁇ g per lane.
- the electrophoresed protein was transferred to a PVDF membrane with a semi-drive mouther and blocked with 5% skim milk.
- Plasma of immunized mice was diluted 200-fold with PBS containing 4% ushi serum albumin and used for the primary antibody reaction.
- an anti-LacZ antibody Promega Z378A
- diluted 5000 times with PBS containing 4% ushi serum albumin was used.
- HRP-labeled anti-mouse Igs Bioso urce AMI4704
- 5% skim milk and 0.1% Tween20 added TBS was used as secondary antibody.
- Signals were detected by chemiluminescence using ECL plus (Amersham) using a LAS1000 instrument (FUJI FILM).
- mice Sixteen-week-old female BALB A mice (4 mice for each route of administration) were diluted with physiological saline by nasal injection, intramuscular injection, direct spleen injection, and footpad injection.
- GFP expression F The gene-deficient Sendai virus vector SeV18 + GFP / ⁇ F (WO00 / 70070) was injected in an amount of 5 ⁇ 10 6 CIU.
- mice under slight anesthesia with sevoflurane were aspirated by a small amount of vector suspension of 100 ⁇ 1 by nasal breathing.
- 50 ⁇ 1 of vector suspension was injected into one leg of the gastrocnemius muscle, and 50 ⁇ 1 of vector suspension was directly injected for spleen direct injection.
- footpad injection each foot was injected with a total of 50 ⁇ l of each foot 25 ⁇ l.
- mice Two 6-week-old female BALB A mice were each administered with the viral vector SeV18 + GFP / AF prepared in saline at 1 xlO 8 ClU / ml subcutaneously in the abdominal cavity or lumbar region. In the abdominal cavity, 100 ⁇ l of the vector suspension was used as it was, and subcutaneous administration was performed by injection of 50 ⁇ l each into two lumbar regions.
- mice After priming 2 weeks, the 5xl0 7 CIU / ml base virus were prepared Kuta one SeV18 + GFP / AF intraperitoneally administered ⁇ ⁇ ⁇ all mice. Control non-boost mice received 100 ⁇ l of saline in the same manner.
- Anti-GFP antibody titer in plasma was detected by Western blotting on commercially available purified GFP protein that was electrophoresed on SDS-PAGE and then transferred and fixed on a PVDF membrane.
- a commercially available anti-GFP antibody and non-immune mouse plasma were used as controls.
- Anti-GFP antibody titer in plasma was electrophoresed on SDS-PAGE, then transferred to PVDF membrane and immobilized on Sendai virus vector-infected LLC-MK cell lysate protein loaded with FP gene
- LLC-MK cells were infected with SeV18 + GFP / AF to a moi of 10, and after 2 days, the cells were washed twice with 4 ° C PBS. After adding 5 ml of cell lysis buffer (PBS supplemented with 10 mM CHAPS, 2 mM EDTA, 2 mM PMSF) and allowing to stand at 4 ° C. for 20 minutes, soluble matter was recovered with a cell scraper. The collected material was centrifuged at 9000 mm, and the supernatant was collected and placed in a permeation tube, Slide-A-Lyzer 2000MW (Piarce). Dialyzed against PBS at 4 ° C to remove CHAPS. . Soluble protein was quantified by the Bradford method (Bio-Rad DC Protein Assembly kit), applied at 5 ⁇ g per lane, and subjected to SDS-PAGE.
- the protein was transferred to a PVDF membrane with a semi-drive lotter and blocked with 5% skim milk or 4% sushi serum albumin.
- Plasma was diluted 200-fold with PBS containing 4% ushi serum albumin and used for the primary antibody reaction.
- an anti-GFP antibody (Invitrogen) diluted 5000 times with PBS containing 4% ushi serum albumin was used.
- Secondary antibody HRP-labeled anti-mouse Igs (Biosource AMI4704) diluted with 5% skim milk, 4% ushi serum albumin, 0.1% Tween 20 supplemented BS was used. Detection was performed by chemiluminescence using ECL plus (Amersham) using a LAS1000 device (FUJI FILM).
- mice 2 weeks after priming, and the viral vectors one SeV18 + GFP / ⁇ F prepared in 5xl0 7 CIU / ml intraperitoneally all mice were administered 100 mu 1. Control non-boost mice received 100 ⁇ l of saline in the same manner.
- the anti-GFP antibody titer in the plasma was detected by Western blotting on commercially available purified GFP protein (Wako chemicals), which was electrophoresed by SDS-PAGE and transferred to a PVDF membrane and fixed as in Example 2.
- a commercially available anti-GFP antibody (Invitrogen) and non-immune mouse plasma were used as controls.
- Example 2 Dilute in saline with saline, intramuscular injection, direct spleen injection, and footpad injection in the same manner as in Example 2 on a total of 8 BALB A mice (2 mice for each administration route) in 6-week-old females.
- the prepared Sendai virus vector SeV18 + GFP / AF was administered at 5 ⁇ 10 6 CIU per head.
- lysate of Sendai virus vector SeV18 + GFP / AF-infected mouse sarcoma cell Meth-A was administered intraperitoneally to all mice in an amount equivalent to 5 X 10 6 cells per head did.
- the lysate was prepared in the same manner as in Example 3.
- the anti-GFP antibody titer in plasma was detected by Western blotting on a commercially purified GFP protein that was electrophoresed on SDS-PAGE and then transferred and fixed on a PVDF membrane.
- a commercially available anti-GFP antibody (Invitrogen) and non-immune mouse plasma were used as controls (FIG. 4).
- virus vector SeV18 + GFP / ⁇ F prepared to 1 xlO 8 CIU / ml with physiological saline was administered intraperitoneally.
- Myeloma (P3_X63-Ag8.653) (RIKEN RCB0146) was cultured in RPMI1640 medium containing 10% fetal bovine serum (FBS), and prepared for the logarithmic growth phase on the day of fusion. On the third day after boosting, the mice were sacrificed by cervical dislocation and the spleen was removed. Using a stainless steel net sterilized in serum-free RPMI1640 medium, spleen cells were isolated by filtration. Spleen cells were washed 3 times and myeloma was washed 2 times with serum-free RPMI1640 medium, and both were mixed at a ratio of 1: 1 and centrifuged.
- FBS fetal bovine serum
- spleen cells and myeloma were fused with 50% polyethylene glycol PEG (Sigma Hybri-Max mw3000_3700). Fused cells are washed with serum-free medium and centrifuged twice, then suspended in 40 ml of RPMI 1640 medium supplemented with 20% FBS / 10 mM HEPES / lmM sodium pyruvate, and added to a 96-well plate at approximately 10 5 cells per well. Sowing.
- HAT selection medium 100 ⁇ l of HAT selection medium to each well, remove half of the medium supernatant from the next day, and add 100 ⁇ l of HAT medium (20% FBS / lxHAT supplement Hybri-Max (Sigma H0262)) RP MI1640 ) was added.
- Half of the medium is exchanged daily in the HAT selection medium until one week after cell fusion, and thereafter in HT medium (Carlo RPMI1640 with 20% FBS / lxHT supplement Hybri-Max (Sigma H0137)). The test was performed every day or according to the density of living cells.
- the fused cells selected by the HAT selection medium When the fused cells selected by the HAT selection medium are large enough to cover more than half of the bottom of the well, collect the culture supernatant and perform Western blotting to obtain anti-GFP antibody from the fused cells. Selected.
- the proliferated fused cells were cloned by limiting dilution using a 96-well plate with BALB A mouse thymocytes as feeders.
- the obtained clones were amplified and became large enough to cover about half of the well, the culture supernatant was recovered, and the clones producing the anti-GFP antibody were recovered by Western blot.
- we succeeded in producing a monoclonal antibody that recognizes GFP using spleen cells of mice immunized with Sendai virus vector loaded with GFP (Fig. 5).
- HIV-1 Human immunodeficiency virus type 1 (HIV-1) envelope protein, gpl60 gene, prepared in 8 x 7-week-old female BALB A mice under sevoflurane anesthesia with 5 xlO 8 CIU / ml in physiological saline F gene-deficient Sendai virus vector SeV18 + GP160 / ⁇ F loaded with 100 ⁇ per nose was administered.
- HAV-1 Human immunodeficiency virus type 1 envelope protein
- gpl60 gene prepared in 8 x 7-week-old female BALB A mice under sevoflurane anesthesia with 5 xlO 8 CIU / ml in physiological saline F gene-deficient Sendai virus vector SeV18 + GP160 / ⁇ F loaded with 100 ⁇ per nose was administered.
- Myeloma (P3-X63-Ag8.653) was prepared by the method described in Example 5.
- 4 animals with high anti-gpl60 antibody titers collected during the final boost were sacrificed by cervical dislocation and the spleen was removed.
- Spleen cells were isolated and collected by grinding the spleen on a nylon mesh in serum-free RPMI 1640 medium.
- Cell fusion of spleen cells and myeloma and culture of the fused cells were performed by the method described in Example 5.
- Antibody-producing cells were identified by detecting culture supernatants that were positive only in the cell.
- g P 160 specific antibody is a Western blot using a PVDF membrane that was transcribed after SDS-PAGE of SeV18 + GP160 / AF vector-infected LLC-MK cell lysate prepared by freezing and thawing.
- Antibodies against viral proteins of HIV and other viruses are useful for detecting and diagnosing viral infections, for example.
- the amino acid sequence of the synthesized peptide is as follows. The number in parenthesis is the amino acid number of the corresponding part on the amino acid sequence of gpl60 registered in Genbank (accession number NPJ357856). However, the # 493 and # 495 amino-terminal cysteines and the # 494 carboxy-terminal cysteine were added for conjugation with KLH and are not included in the gpl60 sequence.
- hybridoma C1-182 producing anti-gpl60 antibody was detected in fusion cells prepared from mice boosted with peptide (FIG. 8). It was determined to be IgG by the C1-182 subclass (6) (Mouse Immunoglobulin Screening / Isotyping Kit (Genzyme, catalog number 97-6550)).
- Cell cloning of 6-76 and C1-182 was performed to enable stable passage of the prepared hyperpridoma. Dilute and inoculate a 96-well tissue culture plate with 0.3, 1, 3 cells / well, and after about 2 weeks, check for a well in which only one cell colony appears per well under a microscope. The supernatant was collected and the presence of anti-gpl60 antibody was detected by ELISA. For cloning, 10% FBS-containing RPMI1640 medium and 10% BM Condimed HI (Roche Diagnostics catalog number 1 088 947) were added for preparation. Cloning was performed twice.
- Example 6 Furthermore, the same positive results as in Example 6 were obtained using the culture supernatants of the second positive cells 6-76-14-21, 6-76-14-29, Cl-182-48-5, CH82-48-35.
- gpl60 and gp41 could be detected in exactly the same way as the original hybridoma and the first cloning positive cells (Fig. 11).
- the antibody protein in the culture supernatant of Hypridoma 6-76-14-29 was purified using a column (Pierce ImmunoPure Immobilized Protein L, catalog number 20510) on which immunoglobulin-binding protein L was immobilized. The protocol followed the attached instructions.
- the purified antibodies were Syp ro Orange fluorescent staining (BioRad catalog number 170-3120), anti-mouse IgG (L + H) antibody (M As with the commercially available anti-Ovalbumin antibody (antibodyshop catalog number HYB 094-07) used as a control in both Western blots according to P Biomedicals catalog number 67428), one band each for H chain and L chain is shown.
- Example 11 Induction of anti-gpl60 antibody in plasma by administration of IL10 co-loaded F gene-deficient Sendai virus vector
- the F gene-deficient Sendai virus vector SeV18 + LacZ / AF contains a nucleic acid encoding cytoforce-in interleukin (IL) -10, which is known to have an effect of stimulating antibody production simultaneously with CT L suppression. Then, a vector loaded with a nucleic acid encoding gpl60 was prepared, and a mouse was immunized using this vector, and the antibody produced in plasma after 56 days was examined. Immunization and Western blot were performed as in Example 7. It was shown that anti-gpl60 antibody is effectively induced by Sendai virus vector loaded with IL-10. ( Figure 15) Industrial applicability
- a method for producing an antibody using a minus-strand RNA viral vector is provided.
- the antibody produced by the method of the present invention is used for protein detection and purification, neutralization, clinical examination, pathological diagnosis, antibody therapy, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006258655A AU2006258655A1 (en) | 2005-06-14 | 2006-06-13 | Method for production of antibody |
CA002612168A CA2612168A1 (en) | 2005-06-14 | 2006-06-13 | Methods for producing antibodies |
US11/922,278 US20110162093A1 (en) | 2005-06-14 | 2006-06-13 | Methods for producing antibodies |
JP2007521301A JP4969444B2 (ja) | 2005-06-14 | 2006-06-13 | 抗体の作製方法 |
EP06766646A EP1916298B1 (en) | 2005-06-14 | 2006-06-13 | Methods for producing monoclonal antibodies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005173851 | 2005-06-14 | ||
JP2005-173851 | 2005-06-14 | ||
JP2005-295451 | 2005-10-07 | ||
JP2005295451 | 2005-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006134917A1 true WO2006134917A1 (ja) | 2006-12-21 |
Family
ID=37532275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/311835 WO2006134917A1 (ja) | 2005-06-14 | 2006-06-13 | 抗体の作製方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110162093A1 (ja) |
EP (1) | EP1916298B1 (ja) |
JP (1) | JP4969444B2 (ja) |
KR (1) | KR20080016955A (ja) |
AU (1) | AU2006258655A1 (ja) |
CA (1) | CA2612168A1 (ja) |
WO (1) | WO2006134917A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2813574B1 (en) * | 2013-06-10 | 2019-02-20 | RSV Genius GmbH | Semi-live respiratory syncytial virus vaccine |
BR112015030697A2 (pt) * | 2013-06-10 | 2017-08-22 | Amvac Ag | Vacina semiviva contra o vírus sincicial respiratório |
WO2015017280A1 (en) * | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6230753B2 (ja) | 1984-08-10 | 1987-07-03 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPS6230752B2 (ja) | 1984-08-09 | 1987-07-03 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPS6233879B2 (ja) | 1984-08-09 | 1987-07-23 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPH03168087A (ja) | 1989-11-28 | 1991-07-19 | Chemo Sero Therapeut Res Inst | 新規発現ベクター |
WO1997016539A1 (fr) | 1995-11-01 | 1997-05-09 | Dnavec Research Inc. | Virus sendai recombinant |
WO1997016538A1 (fr) | 1995-10-31 | 1997-05-09 | Dnavec Research Inc. | Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome |
WO1997032010A1 (fr) | 1996-02-29 | 1997-09-04 | Takara Shuzo Co., Ltd. | Procede pour la purification et l'elimination de virus |
JP2000253876A (ja) * | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
WO2000070055A1 (fr) | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Ribonucleoproteine derivee d'un paramyxovirus |
WO2000070070A1 (fr) | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe |
EP1067179A1 (en) | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
WO2001018223A1 (fr) | 1999-09-06 | 2001-03-15 | Dnavec Research Inc. | Paramoxyvirus possedant une sequence d'initiation de transcription modifiee |
WO2001072340A1 (fr) * | 2000-03-30 | 2001-10-04 | Dnavec Research Inc. | Vaccin contre le virus du sida, contenant un vecteur du virus de sendai |
WO2003025570A1 (en) | 2001-09-18 | 2003-03-27 | Dnavec Research Inc. | Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same |
WO2005042737A1 (ja) * | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
WO2005071092A1 (ja) | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4954796A (en) * | 1995-03-17 | 1996-10-08 | Hisamitsu Pharmaceutical Co., Inc. | Monoclonal antibody specifically recognizing adeno-associated virus cap protein |
US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6054131A (en) * | 1998-01-16 | 2000-04-25 | University Of Maryland Baltimore | Vaccine composition for herpes simplex virus and method of using |
US6828138B1 (en) * | 1998-08-11 | 2004-12-07 | Dnavec Research Inc. | Recombinant sendai virus vector including a gene encoding a chemokine |
US7226786B2 (en) * | 1999-05-18 | 2007-06-05 | Dnavec Research Inc. | Envelope gene-deficient Paramyxovirus vector |
US20030022376A1 (en) * | 1999-05-18 | 2003-01-30 | Kaio Kitazato | Paramyxovirus-derived RNP |
US20030166252A1 (en) * | 1999-05-18 | 2003-09-04 | Kaio Kitazato | Paramyxovirus-derived RNP |
US20020169306A1 (en) * | 1999-05-18 | 2002-11-14 | Kaio Kitazato | Envelope gene-deficient paramyxovirus vector |
US7314614B1 (en) * | 1999-11-02 | 2008-01-01 | Dnavec Research, Inc. | Recombinant sendai virus vector for introducing exogenous genes to airway epithelia |
EP1261708A2 (en) * | 2000-01-14 | 2002-12-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP1311673A2 (en) * | 2000-03-27 | 2003-05-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
JP2002142770A (ja) * | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
WO2002089747A2 (en) * | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO2003029475A1 (en) * | 2001-09-28 | 2003-04-10 | Dnavec Research Inc. | MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF |
WO2003102183A1 (fr) * | 2002-06-03 | 2003-12-11 | Dnavec Research Inc. | Vecteurs de paramyxovirus codant pour un anticorps et son utilisation |
CA2503317A1 (en) * | 2002-10-24 | 2004-05-06 | Dnavec Research Inc. | Method of transferring gene into t cells |
AU2003300956A1 (en) * | 2002-12-11 | 2004-06-30 | Smithkline Beecham Corporation | Anti-infectives |
CA2553377A1 (en) * | 2004-01-13 | 2005-07-28 | Dnavec Research Inc. | Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimaulatory cytokines |
EP1715048A4 (en) * | 2004-01-22 | 2007-02-07 | Dnavec Research Inc | PROCESS FOR PRODUCING A VIRAL VECTOR |
JPWO2005097988A1 (ja) * | 2004-03-23 | 2008-02-28 | 株式会社ディナベック研究所 | 組織の維持および/または修復に関連する骨髄関連細胞 |
JP5296983B2 (ja) * | 2004-06-24 | 2013-09-25 | 株式会社ディナベック研究所 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
KR20080031167A (ko) * | 2005-04-20 | 2008-04-08 | 디나벡크 가부시키가이샤 | 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신 |
CA2636600A1 (en) * | 2006-01-17 | 2007-07-26 | Dnavec Corporation | Novel protein expression system |
WO2007139178A1 (ja) * | 2006-05-31 | 2007-12-06 | Dnavec Corporation | アルツハイマー病治療薬 |
-
2006
- 2006-06-13 KR KR1020087000842A patent/KR20080016955A/ko not_active Application Discontinuation
- 2006-06-13 EP EP06766646A patent/EP1916298B1/en not_active Not-in-force
- 2006-06-13 WO PCT/JP2006/311835 patent/WO2006134917A1/ja active Application Filing
- 2006-06-13 AU AU2006258655A patent/AU2006258655A1/en not_active Abandoned
- 2006-06-13 JP JP2007521301A patent/JP4969444B2/ja not_active Expired - Fee Related
- 2006-06-13 CA CA002612168A patent/CA2612168A1/en not_active Abandoned
- 2006-06-13 US US11/922,278 patent/US20110162093A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6230752B2 (ja) | 1984-08-09 | 1987-07-03 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPS6233879B2 (ja) | 1984-08-09 | 1987-07-23 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPS6230753B2 (ja) | 1984-08-10 | 1987-07-03 | Kagaku Oyobi Ketsusei Ryoho Kenkyusho | |
JPH03168087A (ja) | 1989-11-28 | 1991-07-19 | Chemo Sero Therapeut Res Inst | 新規発現ベクター |
WO1997016538A1 (fr) | 1995-10-31 | 1997-05-09 | Dnavec Research Inc. | Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome |
WO1997016539A1 (fr) | 1995-11-01 | 1997-05-09 | Dnavec Research Inc. | Virus sendai recombinant |
WO1997032010A1 (fr) | 1996-02-29 | 1997-09-04 | Takara Shuzo Co., Ltd. | Procede pour la purification et l'elimination de virus |
JP2000253876A (ja) * | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
WO2000070055A1 (fr) | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Ribonucleoproteine derivee d'un paramyxovirus |
WO2000070070A1 (fr) | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe |
EP1067179A1 (en) | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
WO2001004272A1 (en) | 1999-07-09 | 2001-01-18 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
WO2001018223A1 (fr) | 1999-09-06 | 2001-03-15 | Dnavec Research Inc. | Paramoxyvirus possedant une sequence d'initiation de transcription modifiee |
WO2001072340A1 (fr) * | 2000-03-30 | 2001-10-04 | Dnavec Research Inc. | Vaccin contre le virus du sida, contenant un vecteur du virus de sendai |
WO2003025570A1 (en) | 2001-09-18 | 2003-03-27 | Dnavec Research Inc. | Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same |
WO2005042737A1 (ja) * | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
WO2005071092A1 (ja) | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法 |
Non-Patent Citations (84)
Title |
---|
(NAKANISHI, ET AL.,: "State-of-the-Art Technology Protocol in Neuroscience Research III, Molecular Neuron Physiology", 1993, KOSEISHA, pages: 153 - 172 |
ANJEANETTE ROBERT. ET AL., VIROLOGY, vol. 247, 1998, pages 1 - 6 |
ARAI, T. ET AL., J. VIROL, vol. 72, 1998, pages 1115 - 1121 |
ARAI; T. ET AL., J. VIROLOGY, vol. 72, 1998, pages 1115 - 1121 |
AUSUBEL, F. ET AL.: "Current Protocols in Molecular Biology", vol. 1, 1994, JOHN WILEY AND SONS |
BARON, M. D.; BARRETT, T., J. VIROL., vol. 71, 1997, pages 1265 - 1271 |
BARON, M. D; BARRETT, T., J. VIROL., vol. 71, 1997, pages 1265 - 1271 |
BRIDGEN, A.; ELLIOTT, R. M., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 15400 - 15404 |
CALAIN, P.; ROUX, L., J. VIROL., vol. 67, 1993, pages 4822 - 4830 |
CALOS, M. P., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 3015 |
CAPONI, L. & MIGLIORINI, P.: "Antibody Usage In The Lab, Springer Lab Manual", 1999, SPRINGER-VERLAG |
CHEN, C.; OKAYAMA, H., BIOTECHNIQUES, vol. 6, 1988, pages 632 - 638 |
CHEN, C.; OKAYAMA, H., MOL. CELL. BIOL., vol. 7, 1987, pages 2745 |
CUATRECASAS ET AL., BIOCHEMISTRY, vol. 11, 1972, pages 2291 |
DURBIN, A. P. ET AL., VIROLOGY, vol. 235, 1997, pages 323 - 332 |
DURBIN.A. P. ET AL., VIROLOGY, vol. 235, 1997, pages 323 - 332 |
E. ISHIKAWA ET AL., J. IMMUNOASSAY, vol. 4, 1983, pages 209 |
FOECKING, M.K; HOFSTETTER H., GENE, vol. 45, 1986, pages 101 - 105 |
FUERST, T.R ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 8122 - 8126 |
GARCIN, D. ET AL., EMBO J., vol. 14, 1995, pages 6087 - 6094 |
GARCIN, D., EMBO J., vol. 14, 1995, pages 6087 - 6094 |
GRUN, J. L.; P. H. MAURER, CELLULAR IMMUNOLOGY, vol. 121, 1989, pages 134 - 145 |
HARLOW, E.: "Antibodies; A Laboratory Manual", 1988, COLD SPRING HARBOR |
HASAN, M. K. ET AL., J. GEN. VIROL., vol. 78, 1997, pages 2813 - 2820 |
HASAN, M. K. ET AL., J. GENERAL VIROLOGY, vol. 78, 1997, pages 2813 - 2820 |
HIRATA, T. ET AL., J. VIROL. METHODS, vol. 104, 2002, pages 125 - 133 |
HOLMGREN J, VACCINE, vol. 11, 1993, pages 1179 - 1184 |
HOWARD, C.C. AND BATHELL, D.R.: "Basic Methods in Antibody Production and Characterization", 2001, CRC PRESS |
INOUE M. ET AL., J GENE MED., vol. 6, 2004, pages 1069 - 1081 |
INOUE, K. ET AL., J. VIROL. METHODS, vol. 107, 2003, pages 229 - 236 |
INOUE, M. ET AL., J. VIROL., vol. 77, 2003, pages 6419 - 6429 |
IVAN M. ROITT, JONATHAN BROSTOFF, DAVID K. MALE,: "Immunology, 6th edition", 2001, C.V. MOSBY, article MICHAEL STEWARD: "Immunological Techniques", pages: 417 - 434 |
J. BIOL. CHEM., vol. 272, 1997, pages 16578 - 16584 |
J. V. STAROS, BIOCHEMISTRY, vol. 21, 1982, pages 3950 |
J. VIROLOGY, vol. 39, 1981, pages 519 - 528 |
JOHN E. COLIGAN ET AL: "Current Protocols in Immunology" |
K. FUJIWARA, J. IMMUNOL. METHODS, vol. 112, 1988, pages 77 |
KATO, A ET AL., EMBO J., vol. 16, 1997, pages 578 - 587 |
KATO, A. ET AL., EMBO J., vol. 16, 1997, pages 578 - 587 |
KATO, A. ET AL., GENES CELLS, vol. 1, 1996, pages 569 - 579 |
KATO, A. ET AL., J. VIROL., vol. 71, 1997, pages 7266 - 7272 |
KATO, A., EMBO J., vol. 16, 1997, pages 578 - 587 |
KATO, A., GENES CELLS, vol. 1, 1996, pages 569 - 579 |
KOLAKOFSKI, D., J. VIROL., vol. 72, 1998, pages 891 - 899 |
KRIEG, P.A.; MELTON, D.A., METHODS ENZYMOL., vol. 155, 1987, pages 397 - 15 |
KRUSE N, EMBO J., vol. 12, 1993, pages 5121 - 5129 |
LAWSON, N. D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, pages 4477 - 4481 |
LELAND, P ET AL., ONCOL. RES., vol. 7, 1995, pages 227 - 235 |
LI, H.-O. ET AL., J. VIROL., vol. 74, 2000, pages 6564 - 6569 |
LI, H.-O. ET AL., J. VIROL., vol. 74, no. 14, 2000, pages 6564 - 6569 |
LINDSAY DS ET AL., INT ARCH ALLERGY IMMUNOL, vol. 105, 1994, pages 281 - 288 |
M. J. O'SULLIVAN ET AL., ANAL. BIOCHEM., vol. 100, 1979, pages 100 |
MILLIGAN, J.F. ET AL., NUCLEIC ACIDS RES., vol. 15, 1987, pages 8783 - 798 |
NIWA, H. ET AL., GENE, vol. 108, 1991, pages 193 - 199 |
OKANO M ET AL., J IMMUNOL., vol. 167, no. 1, 2001, pages 442 - 50 |
OLD, L. ET AL., ANN. N.Y ACAD. SCI., vol. 101, 1962, pages 80 - 106 |
OSHIMA Y ET AL., J BIOL CHEM, vol. 276, 2001, pages 15185 - 91 |
OSHIMA, Y ET AL., J. BIOL. CHEM, vol. 275, 2000, pages 14375 - 14380 |
PETER J. DELVES: "Antibody Production: Essential Techniques", 1997, JOHN WILEY & SONS |
POKROVSKAYA, LD.; GUREVICH, V.V., ANAL. BIOCHEM., vol. 220, 1994, pages 420 - 23 |
R. KONTERMANN & S. DUBEL: "Antibody Engineering", 2001, SPRINGER VERLAG |
RADECKE, F. ET AL., EMBO J., vol. 14, 1995, pages 5773 - 5784 |
ROSENTHAL, N., METHODS ENZYMOL., vol. 152, 1987, pages 704 - 709 |
S. YOSHITAKE ET AL., ANAL. LETT., vol. 15, 1982, pages 147 |
S. YOSHITAKE ET AL., EUR. J. BIOCHEM., vol. 101, 1979, pages 395 |
S. YOSHITAKE ET AL., SCAND. J. IMMUNOL., vol. 10, 1979, pages 81 |
SAITO ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 3816 - 3821 |
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY |
SCHNELL. M. J. ET AL., EMBO J., vol. 13, 1994, pages 4195 - 4203 |
See also references of EP1916298A4 * |
SHINNIK, T. M.; LERNER, R. A.; SUTCLIFFE, NATURE, vol. 293, 1981, pages 543 - 548 |
STRAHLE ET AL., J. VIROL., vol. 77, no. 14, 2003, pages 7903 - 7913 |
TASHIRO, M.: "VlfUS Experiment Protocol", 1995, MEDICAL VIEW CO., pages: 68 - 73 |
THE JAPANESE BIOCHEMICAL SOCIETY: "Shinseikagaku Jikken Koza 12 Bunshi Men'ekigaku III- Kogen Kotai Hotai-", TOKYO KAGAKU DOJIN, vol. 1ST EDITION, 5 February 1992 (1992-02-05), pages 1 - 2, AND 6 - 7, AND 25 - 27, XP003007676 * |
THOMPSON-SNIPES, L. ET AL., J. EXP. MED., vol. 173, 1991, pages 507 - 510 |
TOKUSUMI, T. ET AL., VIRUS RES., vol. 86, 2002, pages 33 - 38 |
TSUTSUMI ET AL., PEDIATR. INFECT. DIS. J., vol. 20, no. 10, 2001, pages 997 - 1001 |
WHELAN, S. P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8388 - 8392 |
WHELAN, S. P. ET AL., PROC: NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8388 - 8392 |
WILLIAM C. DAVIS: "Methods in Molecular Biology", vol. 45, 1995, HUMANA PRESS INC., article "Monoclonal Antibody Protocols." |
WILSON AD ET AL., VACCINE, vol. 11, 1993, pages 113 - 118 |
XU-AMANO J ET AL., J EXP MED, vol. 178, 1993, pages 1309 - 1320 |
YONEMITSU Y. ET AL., NAT BIOTECHNOL, vol. 18, no. 9, 2000, pages 970 - 3 |
YU, D. ET AL., GENES CELLS, vol. 2, 1997, pages 457 - 466 |
Also Published As
Publication number | Publication date |
---|---|
EP1916298A1 (en) | 2008-04-30 |
AU2006258655A1 (en) | 2006-12-21 |
KR20080016955A (ko) | 2008-02-22 |
EP1916298A4 (en) | 2009-04-08 |
CA2612168A1 (en) | 2006-12-21 |
EP1916298B1 (en) | 2011-12-28 |
JPWO2006134917A1 (ja) | 2009-01-08 |
JP4969444B2 (ja) | 2012-07-04 |
US20110162093A1 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7521043B2 (en) | Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines | |
JP2012144541A (ja) | センダイウイルスベクターを用いたaidsウイルスワクチン | |
US20060104950A1 (en) | Methods of Tranducing genes into T cells | |
US20090170798A1 (en) | Highly safe intranasally administrable gene vaccines for treating alzheimer's disease | |
US20120087940A1 (en) | Vector for treating alzheimer's disease | |
US20050191617A1 (en) | Pramyxovirusl vectors encoding antibody and utilization thereof | |
JPWO2003029475A1 (ja) | エピトープ結合β2mをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用 | |
JP4969444B2 (ja) | 抗体の作製方法 | |
WO2006137517A1 (ja) | 幼少個体への遺伝子導入用ベクター | |
US10828359B2 (en) | Anti-Mycobacterium tuberculosis vaccine using sendai virus as vector | |
EP2363472B1 (en) | Method for enhancing expression of recombinant protein | |
JP4903159B2 (ja) | アルツハイマー病の治療のための安全性に優れた鼻腔内投与可能遺伝子ワクチン | |
EP1642966B1 (en) | Minus strand rna viral vectors carrying a gene with altered hypermutable regions | |
CN101243179A (zh) | 制备抗体的方法 | |
Suryanarayana et al. | Non-segmented negative sense RNA viruses as vectors for vaccine development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680029696.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007521301 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2612168 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087000842 Country of ref document: KR Ref document number: 2006766646 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006258655 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006258655 Country of ref document: AU Date of ref document: 20060613 Kind code of ref document: A |